封面
市場調查報告書
商品編碼
1190729

Elispot 和 Fluorospot 檢測市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Elispot and Fluorospot Assay Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內(2022 年至 2027 年),Elispot 和 Fluorospot 檢測市場預計將以超過 13.3% 的全球複合年增長率增長。

COVID-19 大流行影響了全球醫療保健系統,也對 Elispot 和 Fluorospot 檢測市場產生了重大影響。 根據 2020 年發表的一篇 Medtech 文章,COVID-19 中的抗體滴度和 T 細胞反應性之間似乎存在聯繫。 在抗體滴度最低的三名 COVID-19 患者(C4、C5、C7)的 FluoroSpot 檢測中,觀察到最多數量的 IFN-/IL-2 分泌細胞和最強的 T 細胞反應。 因此,Elispot 和 Fluorospot 已被用於 COVID-19 患者,以確認 SARS-CoV-2 特異性 T 細胞和 B 細胞免疫力。

推動 Elispot 和 Fluorospot 檢測市場增長的關鍵因素是疫苗研究的興起以應對耐藥菌株的挑戰、全球慢性病發病率的增加、推動 Elispot 和 Fluorospot 檢測市場的增長。ELISpot 的創新和 FluoroSpot 分析儀和檢測試劑盒。 根據 Globocan 2020 Fact Sheet,全球估計有 19,292,789 例新診斷的癌症病例和大約 9,958,133 例癌症死亡病例。 此外,國際癌症研究機構 (IARC) 估計,到 2040 年,全球癌症負擔預計將導致 2750 萬新癌症病例和 1630 萬死亡病例增加。 由於癌症患者的增加,預計 Elispot 和 Flurospot 檢測的市場需求將會增加。 根據世界衛生組織 (WHO) 2021 年 4 月更新,非傳染性疾病 (NCD) 每年導致 4100 萬人死亡(佔全球所有死亡人數的 71%),超過 1500 萬人死於 69 至 69 歲之間的非傳染性疾病,而這些“過早”死亡中有 85% 發生在低收入和中等收入國家。 因此,增加慢性病的患病率以促進市場研究。

ELISpot 是許多疾病疫苗開發的重要途徑:艾滋病、結核病、艾滋病毒、瘧疾、癌症、流感等。 ELISpot 測試是臨床試驗中用於評估疫苗的最廣泛使用的免疫測定之一。 該評估主要基於樣本敏感性、統計可讀性以及在大規模篩選和個體研究中的易用性。 該測試可用於評估 T 細胞反應和產生疫苗特異性抗體的 B 細胞。

因此,考慮到上述因素,預計癌症治療市場在預測期內將出現巨大增長。

Elispot 和 Fluorospot 分析市場趨勢

Elispot 和 Fluorospot 檢測市場,檢測試劑盒有望佔據最大市場份額

檢測試劑盒廣泛應用於生命科學研究、藥物開發和環境監測,包括疾病途徑調查、有希望的候選藥物篩選以及生物製藥生產過程評估。

由於慢性病發病率高以及臨床試驗中越來越多地使用疫苗開發產品等因素,檢測試劑盒佔據了市場主導地位。

根據世界衛生組織 (WHO) 2020 年 12 月的數據,目前主要慢性病佔全球死亡人數的 60% 左右,佔疾病負擔的 43% 左右。 到 2020 年,預計死亡人數將增加到 73%,發病率將增加到 60%。 在新興市場,79% 的死亡是由於慢性病。 此外,ELISpot 和 FluoroSpot 檢測試劑盒和分析儀的技術創新也有望推動市場增長。

北美主導市場,預計在預測期內也會如此

在整個預測期內,預計北美將主導整個 Elispot 和 Fluorospot 檢測市場。 這是由於諸如傳染病等慢性病患病率上升和老年人口不斷增加等因素造成的。

根據 Globocan 2020 報告,估計 2020 年美國將診斷出 2,281,658 例新癌症病例。 2020 年美國最常見的癌症是乳腺癌 (253,465)、肺癌 (227,875)、前列腺癌 (209,512) 和結腸癌 (101,809)。 與其他發達國家相比,美國是某些慢性病(如癌症和心血管疾病)患病率最高的國家之一,這將對該國研究市場的增長產生重大影響。存在這種可能性。

此外,根據美國疾病控制與預防中心 2021 年的數據,在美國,心髒病、癌症和糖尿病等慢性病是導致死亡和殘疾的主要原因。 他們也是美國每年 3.8 萬億美元醫療保健支出的主要驅動力。 因此,慢性病患病率上升和醫療成本上升將是預測期內推動該國市場的因素。

Elispot 和 Fluorospot 檢測市場的競爭分析

Elispot 和 Fluorospot 檢測市場競爭激烈,由幾家大型企業組成。 就市場份額而言,目前幾家主要參與者主導著市場。 一些知名企業正在積極收購其他公司或推出新產品,以鞏固其在全球的市場地位。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 慢性病發病率增加
    • ELISpot 和 FluoroSpot 檢測試劑盒及分析儀的技術突破
  • 市場製約因素
    • 替代檢測技術的可用性
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模:百萬美元)

  • 按產品分類
    • 分析儀
    • 檢測試劑盒
    • 輔助產品
  • 最終用戶
    • 醫院和研究機構
    • 生物製藥公司
    • 研究所
  • 通過申請
    • 調查
      • 疫苗開發
      • 臨床試驗
      • 癌症研究
    • 診斷
      • 感染
      • 移植
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Becton, Dickinson and Company
    • U-Cytech Biosciences
    • Cellular Technologies Limited
    • Mabtech AB
    • Abcam
    • Autoimmun Diagnostika GmbH
    • Lophius Biosciences GmbH
    • Bio-Connect B.V.
    • Oxford Immunotec
    • Bio-Techne Corporation

第7章 市場機會今後動向

簡介目錄
Product Code: 67517

The ELISpot and FluoroSpot Assay Market is expected to grow at a CAGR of more than 13.3%*globally during the forecast period (2022-2027).

The COVID-19 pandemic has affected the healthcare systems globally and also has had a significant impact on the ELISpot and FluoroSpot assay market. According to the article by Medtech published in 2020, there seems to be a link between antibody titers and T-cell responsiveness in COVID-19. The strongest T cell response was observed as the highest number of IFN-/IL-2 secreting cells in a FluoroSpot assay in three individuals (C4, C5, and C7) with the lowest antibody response in COVID-19 patients. Thus, to check the SARS-CoV-2-specific T- and B-cell immunity, the elispot and flurospot are used in COVID-19 patients.

The major factors attributing to the growth of the ELISpot and FluoroSpot assay market are the rising vaccine research to tackle the drug-resistant strains challenge, the growing global occurrence of chronic illnesses, and technological innovations in ELISpot and FluoroSpot analyzers and assay kits which are assessed to upsurge the market growth for ELISpot and FluoroSpot assay. According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths due to cancers globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. The increasing incidence of cancer cases is expected to drive the need for elispot and flurospot assay markets. In addition, according to an April 2021 update by the World Health Organization (WHO), non-communicable diseases (NCDs) kill 41 million people each year, equivalent to 71% of all deaths globally, and each year, more than 15 million people die from an NCD between the ages of 30 and 69 years; 85% of these "premature" deaths occur in low- and middle-income countries. Thus increasing the prevalence of chronic diseases to boost the market study.

ELISpot is a crucial path to vaccine development for many illnesses, namely AIDS, tuberculosis, HIV, malaria, cancer, and flu. The ELISpot test is among the most widely utilized immunoassays in clinical studies to assess vaccines. This reputation was based mainly on the higher sensitivity of the sample, statistical read-out, and ease of use in both large screening and individual tests. The test can be used to assess both T-cell reactions and vaccine-specific antibody-producing B cells.

Thus, given the aforementioned factors, the cancer therapy market is expected to witness tremendous growth over the forecast period.

ELISpot and FluoroSpot Assay Market Trends

Assay Kits is Expected to Hold the Largest Market Share in the ELISpot and FluoroSpot Assay Market

Assay kits are employed in a wide range of applications in life science research, drug development, and environmental monitoring, including researching disease pathways, screening for prospective drug candidates, and evaluating biopharmaceutical production processes.

Dominant share is retained by the assay kits segment owing to the factors such as a high incidence of chronic ailments and increased use of these products for vaccine development in clinical studies.

As per the (WHO) World Health Organization December 2020, the main chronic illnesses presently make up nearly 60% of all fatalities and 43% of the worldwide disease burden. Their contribution is projected to increase up to 73% of all fatalities by 2020 and 60% of the worldwide morbidity. In addition, in developing countries, 79% of the deaths take place owing to chronic diseases. Furthermore, the technological innovation of assay kits and analyzers for ELISpot and FluoroSpot is also expected to drive market growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall ELISpot and FluoroSpot assay market throughout the forecast period. This is owing to factors such as the rising prevalence of chronic disorders such as infectious diseases and the geriatric population.

According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases will be diagnosed in United States in 2020. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in United States. United States has one of the highest prevalences of some chronic diseases, such as cancer and cardiovascular diseases, as compared to other developed countries, which may have a significant impact on the growth of the studied market in the country.​

Furthermore, according to the Center for Disease Control and Prevention 2021, in United States, chronic diseases such as heart disease, cancer, and diabetes are the main causes of mortality and disability. They are also the main drivers of the USD3.8 trillion in annual healthcare spending in United States. Thus rising prevalence of chronic diseases and growing healthcare spending boost the market in the country over the forecast period.

ELISpot and FluoroSpot Assay Market Competitive Analysis

The ELISpot and FluoroSpot assay market is moderately competitive and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and new product launches with the other companies to consolidate their market positions across the globe.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidence of Chronic Diseases
    • 4.2.2 Technological Breakthroughs in Test Kits and analyzers for ELISpot and FluoroSpot
  • 4.3 Market Restraints
    • 4.3.1 Availability of alternative detection technologies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Analyzers
    • 5.1.2 Assay kits
    • 5.1.3 Ancillary Products
  • 5.2 By End User
    • 5.2.1 Hospitals & Clinical labs
    • 5.2.2 Biopharmaceutical Company
    • 5.2.3 Research Institutes
  • 5.3 By Application
    • 5.3.1 Research
      • 5.3.1.1 Vaccine Development
      • 5.3.1.2 Clinical Trials
      • 5.3.1.3 Cancer Research
    • 5.3.2 Diagnostics
      • 5.3.2.1 Infectious Disease
      • 5.3.2.2 Transplants
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 U-Cytech Biosciences
    • 6.1.3 Cellular Technologies Limited
    • 6.1.4 Mabtech AB
    • 6.1.5 Abcam
    • 6.1.6 Autoimmun Diagnostika GmbH
    • 6.1.7 Lophius Biosciences GmbH
    • 6.1.8 Bio-Connect B.V.
    • 6.1.9 Oxford Immunotec
    • 6.1.10 Bio-Techne Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS